A citation-based method for searching scientific literature

Hanan Ahmed Wahba, Hend Ahmed El-Hadaad. Cancer Biol Med 2015
Times Cited: 298







List of co-cited articles
415 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni. Nat Rev Clin Oncol 2016
15

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
15

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
12

Breast Cancer Treatment: A Review.
Adrienne G Waks, Eric P Winer. JAMA 2019
11

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
11

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
11



Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu. Breast Cancer Res 2020
409
9

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
8

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, Xi Chen, Monica V Estrada, Kimberly N Johnson, Yu Shyr, Harold L Moses, Melinda E Sanders, Jennifer A Pietenpol. PLoS One 2016
640
8


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
8

Advances in the systemic treatment of triple-negative breast cancer.
J M Lebert, R Lester, E Powell, M Seal, J McCarthy. Curr Oncol 2018
149
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7

Recent advances in triple negative breast cancer: the immunotherapy era.
Antonio Marra, Giulia Viale, Giuseppe Curigliano. BMC Med 2019
177
7


Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis.
Christiana Neophytou, Panagiotis Boutsikos, Panagiotis Papageorgis. Front Oncol 2018
89
7

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Peter Schmid, Hope S Rugo, Sylvia Adams, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Volkmar Henschel, Luciana Molinero, Stephen Y Chui,[...]. Lancet Oncol 2020
540
7


Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
831
7


Breast cancer.
Nadia Harbeck, Frédérique Penault-Llorca, Javier Cortes, Michael Gnant, Nehmat Houssami, Philip Poortmans, Kathryn Ruddy, Janice Tsang, Fatima Cardoso. Nat Rev Dis Primers 2019
886
6

STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang. J Exp Clin Cancer Res 2019
172
6

A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Katsuya Nakai, Mien-Chie Hung, Hirohito Yamaguchi. Am J Cancer Res 2016
188
6

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
S Adams, P Schmid, H S Rugo, E P Winer, D Loirat, A Awada, D W Cescon, H Iwata, M Campone, R Nanda,[...]. Ann Oncol 2019
381
6

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
5

The hallmarks of cancer.
D Hanahan, R A Weinberg. Cell 2000
5

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
756
5

Recent advances in nanotheranostics for triple negative breast cancer treatment.
Vikram Thakur, Rajaletchumy Veloo Kutty. J Exp Clin Cancer Res 2019
75
6

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
5

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Carsten Denkert, Cornelia Liedtke, Andrew Tutt, Gunter von Minckwitz. Lancet 2017
434
5

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer.
So-Yeon Park, Jang-Hyun Choi, Jeong-Seok Nam. Cancers (Basel) 2019
91
5

Metastatic and triple-negative breast cancer: challenges and treatment options.
Sumayah Al-Mahmood, Justin Sapiezynski, Olga B Garbuzenko, Tamara Minko. Drug Deliv Transl Res 2018
218
5


Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
713
5


Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
Charissa Kim, Ruli Gao, Emi Sei, Rachel Brandt, Johan Hartman, Thomas Hatschek, Nicola Crosetto, Theodoros Foukakis, Nicholas E Navin. Cell 2018
455
4

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
4

Triple-negative breast cancer and the potential for targeted therapy.
Jing-Ru Jhan, Eran R Andrechek. Pharmacogenomics 2017
122
4

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
587
4

Understanding and treating triple-negative breast cancer.
Carey Anders, Lisa A Carey. Oncology (Williston Park) 2008
216
4

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,[...]. Proc Natl Acad Sci U S A 2005
4

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Ricardo L B Costa, Hyo Sook Han, William J Gradishar. Breast Cancer Res Treat 2018
222
4

Triple-negative breast cancer: is there a treatment on the horizon?
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol, Xiyun Deng. Oncotarget 2017
189
4

Breast cancer intrinsic subtype classification, clinical use and future trends.
Xiaofeng Dai, Ting Li, Zhonghu Bai, Yankun Yang, Xiuxia Liu, Jinling Zhan, Bozhi Shi. Am J Cancer Res 2015
487
4

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Hiroko Masuda, Keith A Baggerly, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, Vicente Valero, Brian D Lehmann, Jennifer A Pietenpol, Gabriel N Hortobagyi,[...]. Clin Cancer Res 2013
457
4

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
4

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
4



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.